Keros Therapeutics (KROS) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Pyxis Oncology (PYXS) over the past year, losing 27.1% versus a loss of 31.6%. Over five years, KROS leads with a -70.1% price change compared with -83.1% for PYXS. Pyxis Oncology is the larger company by market cap ($238.9 million vs $232.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | PYXS |
|---|---|---|
| Share price | $11.74 | $2.00 |
| Market cap | $232.86M | $238.91M |
| 1-day change | +0.90% | +0.50% |
| YTD return | -42.83% | +73.04% |
| 1-year return | -27.07% | -31.62% |
| 5-year return | -70.15% | -83.09% |
| EPS (TTM) | $-3.22 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $5.55 |
| 52-week low | $9.69 | $1.03 |
| Distance from 52-week high | -47.92% | -63.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +68.84% | +333.50% |
| Average volume | 194.05K | 1.26M |
| Shares outstanding | 19.83M | 119.46M |
| Employees | 92 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
KROS vs PYXS FAQ
Which is bigger, Keros Therapeutics or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $238.91M compared with $232.86M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, KROS or PYXS?
KROS returned -27.07% over the past 12 months, compared with -31.62% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.